LIPO — Lipella Pharmaceuticals Balance Sheet
0.000.00%
- $6.41m
- $4.23m
- $0.54m
Annual balance sheet for Lipella Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.607 | 1.71 | 5.12 | 3.29 | 2.18 |
Net Total Receivables | 0.069 | 0 | 0.114 | 0.032 | 0.085 |
Prepaid Expenses | |||||
Total Current Assets | 0.699 | 1.81 | 5.8 | 3.43 | 2.62 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.256 | 0.205 | 0.151 | 0.148 | 0.057 |
Total Assets | 0.955 | 2.01 | 5.95 | 3.58 | 2.67 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 0.208 | 0.341 | 1.18 | 0.385 | 0.754 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.492 | 0.589 | 1.27 | 0.433 | 0.754 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 0.463 | 1.42 | 4.68 | 3.14 | 1.92 |
Total Liabilities & Shareholders' Equity | 0.955 | 2.01 | 5.95 | 3.58 | 2.67 |
Total Common Shares Outstanding |